GlassScriptPhysician profile
Olga T Perez
NPI 1043487218
$4,161.21
in general payments reported to CMS, 2019-2025
36 companies · $64.49 in 2025
The $64.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $826 · 2021: $726 · 2022: $575 · 2023: $598 · 2024: $323 · 2025: $64.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.38 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $792.21 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $334.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $279.58 | 2019-2024 | Airsupra, Andexxa |
| Abbvie INC. | $265.27 | 2021-2023 | |
| Pfizer INC. | $245.12 | 2019-2023 | |
| Glaxosmithkline, LLC. | $192.11 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $125.06 | 2019-2021 | |
| Redhill Biopharma INC. | $97.31 | 2020 | |
| Allergan, INC. | $94.02 | 2019-2020 | |
| Gilead Sciences, INC. | $81.09 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.54 | 2019-2023 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $52.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.98 | 2022 | |
| Boston Scientific Corporation | $44.01 | 2025 | Watchman Flx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $43.22 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $42.68 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $42.49 | 2019 | |
| Abbott Laboratories | $37.95 | 2022-2023 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.09 | 2019-2021 | |
| Eisai INC. | $35.90 | 2020-2021 | |
| Horizon Therapeutics Plc | $33.17 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $30.92 | 2022 | |
| Amgen INC. | $29.27 | 2019-2023 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $28.02 | 2024 | Voquezna |
| Antares Pharma, INC. | $22.68 | 2023 | Xyosted, Tlando, Nocdurna |
| Viiv Healthcare Company | $22.35 | 2024 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $18.55 | 2019 | |
| Ibsa Pharma INC. | $18.11 | 2022 | |
| Nabriva Therapeutics, Plc | $17.90 | 2022 | |
| Vifor Pharma, INC. | $17.77 | 2019 | |
| Tolmar, INC. | $14.95 | 2024 | |
| Zimmer Biomet Holdings, INC. | $13.12 | 2019 | |
| Genentech USA, INC. | $12.24 | 2020 | |
| Avion Pharmaceuticals | $11.88 | 2019 | |
| Merck Sharp & Dohme LLC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.